Clinical Trial News and Research

RSS

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2012.

31 Jul 2012

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012

Treatments for peripheral neuropathic pain compared

The first study to compare the 8% capsaicin patch with pregabalin as a treatment for peripheral neuropathic pain begins, with enrolment of the first patient.

31 Jul 2012

Advanced understanding of neurodegenerative diseases achieved by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.

31 Jul 2012

Stem cell therapy holds promise for craniofacial bone repair

In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues-mainly bone-proved quicker, more effective and less invasive than traditional bone regeneration treatments.

31 Jul 2012

HPV co-testing prospect for HIV-infected women

The risk for cervical precancer and cancer is similar in HIV-infected and HIV-uninfected women with normal cervical cytology and no evidence of oncogenic human papillomavirus infection, research shows.

30 Jul 2012

Some AIDS experts view health law coverage expansion with hope

Meanwhile, the Obama administration announced it would add new funds to increase access to HIV/AIDS care, but questions remain about whether it will be enough to address waiting lists for the drug assistance program. Also in the news, reports on treatment developments.

30 Jul 2012

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.

30 Jul 2012

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

30 Jul 2012

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

30 Jul 2012

Cedars-Sinai to develop stem cell treatments for patients with ALS

Cedars-Sinai Regenerative Medicine Institute today was awarded a $17.8 million grant from the California Institute for Regenerative Medicine to develop stem cell treatments for patients with ALS, also known as Lou Gehrig's Disease, a progressive, fatal and currently incurable neurodegenerative disease.

30 Jul 2012

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

"The world's first vaccine against dengue fever, being developed by French drugmaker Sanofi SA, protected against three of the virus's four strains in a keenly awaited clinical trial in Thailand," the company announced on Wednesday, Reuters reports.

28 Jul 2012

Anakinra can dramatically limit amount of brain damage in stroke patients

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

From The University of Manchester 27 Jul 2012

Rate of new HIV infections among young U.S. black MSM is high: Study

The rate of new HIV infections among black men who have sex with men (MSM) in the United States, particularly younger men, is high and suggests the need for prevention programs specifically tailored to this population, according to initial findings from the HPTN 061 study.

27 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

26 Jul 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

Clinical Trial News and Research

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

Treatments for peripheral neuropathic pain compared

Advanced understanding of neurodegenerative diseases achieved by Trophos

Stem cell therapy holds promise for craniofacial bone repair

HPV co-testing prospect for HIV-infected women

Some AIDS experts view health law coverage expansion with hope

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Cedars-Sinai to develop stem cell treatments for patients with ALS

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

Anakinra can dramatically limit amount of brain damage in stroke patients

Rate of new HIV infections among young U.S. black MSM is high: Study

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer